Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GDC-0917 |
Synonyms | |
Therapy Description |
GDC-0917 (CUDC-427) is a SMAC mimetic, which acts as an antagonist to Inhibitor of Apoptosis Protein (IAP) family proteins, resulting in decreased tumor growth (PMID: 24041744, PMID: 27076626). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GDC-0917 | CUDC-427|RG7459 | SMAC Mimetic 8 | GDC-0917 (CUDC-427) is a SMAC mimetic, which acts as an antagonist to Inhibitor of Apoptosis Protein (IAP) family proteins, resulting in decreased tumor growth (PMID: 24041744, PMID: 27076626). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01908413 | Phase I | GDC-0917 | Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma | Terminated | USA | 0 |